Navigation Links
Sanofi Pasteur Shipping First Doses of Influenza Vaccine for the 2008-2009 Season
Date:7/31/2008

SWIFTWATER, Pa. and LYON, France, Aug. 1 /PRNewswire/ -- Sanofi Pasteur, the vaccines division of sanofi-aventis Group, began shipping influenza vaccine (Fluzone(R), Influenza Virus Vaccine) in the United States for the 2008-2009 season. The first 1.3 million doses of influenza vaccine began shipping this week following marketing clearance of the 2008-2009 formulation by the U.S. Food and Drug Administration (FDA) on July 14, 2008.

Vaccine shipments to health-care providers and to the Centers for Disease Control and Prevention (CDC) for distribution through the Vaccines for Children Program will continue through the fall and are planned to be completed in October.

This year's influenza vaccine contains three new strains of the influenza virus, A/Brisbane/59/2007 (H1N1)-like virus; A/Brisbane/10/2007 (H3N2)-like virus; B/Florida/4/2006-like virus. The three strains for the new influenza vaccine formulation were confirmed by the FDA's Vaccines and Related Biological Products Advisory Committee in February 2008 and correspond with recommendations made by the World Health Organization in February. Unlike other routinely recommended vaccines whose formulation remains constant over time, influenza vaccine is formulated each year to match the strains predicted to circulate during the upcoming season.

"Introduction of three new strains for the influenza vaccine was unprecedented and could have resulted in a low yield or delay given our tight production timeline. Despite these challenges, we are pleased that once again sanofi pasteur has demonstrated its reliability in supplying Fluzone vaccine to the U.S. market," said Wayne Pisano, President and Chief Executive Officer, sanofi pasteur. "The early shipment of Fluzone vaccine by sanofi pasteur gives health-care providers greater flexibility in planning their vaccination efforts."

As the world's leading influenza vaccine manufacturer, sanofi pasteur produces approximately half of the influen
'/>"/>

SOURCE Sanofi Pasteur
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. ThalesNano Inc. and sanofi-aventis R&D Collaborate on Continuous Process Chemistry in Order to Dramatically Reduce Drug Realization Time
2. U.S. Government Accepts $192 Million of sanofi pasteur H5N1 Bulk Vaccine Antigen for Pandemic Stockpile
3. Sanofi Pasteur Mounts Emergency Response to Yellow Fever Epidemic in Latin America
4. Sanofi-aventis SoloSTAR(R) Insulin Pen for Lantus and Apidra Receives the Prestigious GOOD DESIGN Award
5. Sanofi Pasteur and Statens Serum Institut Team Up Against Tuberculosis
6. Shareholder Class Action Filed Against Sanofi-Aventis by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
7. Maxygen Licenses Dengue Vaccine Technology to sanofi pasteur
8. Sanofi Pasteurs Investigational H5N1 Influenza Vaccine Achieves High Immune Response at low Dosage
9. Sanofi-aventis Announces Settlement of Average Wholesale Price Civil Suits With the U.S. Department of Justice Relating to Anzemet(R)
10. Pasteuria Bioscience Taps New CEO David N. Duncan
11. SPO Medical Begins Shipping PulseOx 6000(TM) and PulseOx 6100(TM)

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2009)..., PARIS, November 27 /PRNewswire-FirstCall/...l to market Oralair(R) in both adults and children...the first country where,Oralair(R) has been market...lair(R) is now registered in Austria, Belgium, Bul..., Germany, Greece, Hungary, Ireland, Italy,Latvia...
(Date:11/25/2009)... , BOSTON, Nov. 25 Biotech...virus, genomic data from the 1918 pandemic through...rent H1N1 pandemic, today issued its latest bioche...at the lethality of the H1N1 ("Swine Flu") virus h...the virus,s current outbreak in the spring of 2009...
(Date:11/25/2009)... , BEIJING, Nov. 25 /PRNewswire-Asia/...er and provider of vaccines, announced today that ...blish Sinovac (Dalian) Vaccine,Technology Co., Ltd... produce,and commercialize human-use vaccines. Sin...in developing and commercializing world-class vacc...
(Date:11/24/2009)... , HOUSTON, Nov. 24 /PRNewswire-FirstCall/ -...r of electrical and communications systems and ser...al markets, announced today that its commercial bu...attan Torcon JV to install the electrical systems ... facility at the U.S. Army Medical Research Instit...
Breaking Biology Technology:STALLERGENES is Granted a Marketing Authorization for Oralair(R) in Europe 2STALLERGENES is Granted a Marketing Authorization for Oralair(R) in Europe 3Biological H1N1 Vaccines: Too Little, Too Late 2Biological H1N1 Vaccines: Too Little, Too Late 3Biological H1N1 Vaccines: Too Little, Too Late 4Biological H1N1 Vaccines: Too Little, Too Late 5Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities 2Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities 3Integrated Electrical Services Awarded Contract to Provide Electrical Systems for U.S. Army Medical Research Institute of Infectious Diseases 2
...launch..., WAYLAND, Mass., March 20 Tourtellotte...clinical trials software, announces the,launch of ...orm for phase,II-IV studies. Trident,s unique para... of legacy IVRS technologies and promises to deliv...and ease-of-use to the straining,global clinical I...
...Inc., a,pioneer in drug discovery from marine micr... begun in a Phase 1b study evaluating the vascular...th standard chemotherapy,in patients with non-smal...positive outcomes in a Phase 1 single-agent clinic...harmacodynamics (PK/PD) and efficacy of NPI-2358,i...
...ian acceptance of electrophysiology ablation as...lation, according to Millennium Research Group, W...esearch Group,s Global Markets for Atrial Fibrilla...00 electrophysiology (EP) procedures were,performe... procedure,volumes will increase at a compound ann...
Other Biology Technology:Tourtellotte's New Trident IWR(TM) Eliminates 12-Week Study Setup Lead Time for Clinical Trials 2Tourtellotte's New Trident IWR(TM) Eliminates 12-Week Study Setup Lead Time for Clinical Trials 3Nereus Pharmaceuticals Initiates Clinical Trial of NPI-2358 in Non-Small Cell Lung Cancer Following Encouraging Phase 1 Data 2Nereus Pharmaceuticals Initiates Clinical Trial of NPI-2358 in Non-Small Cell Lung Cancer Following Encouraging Phase 1 Data 3Electrophysiology Procedures for Atrial Fibrillation Treatment to Grow Over 25% Annually Over the Next Five Years 2
(Date:11/23/2009)...s. November 23, 2009 Applied mathematicians diss...lancifolia ), a characteristic long leaf with a sa...s along the edges. The simple cause of the lily,s ...nding during differential growthwas revealed by us...ibbons. , Haiyi Liang, a postdoctoral student at...
(Date:11/23/2009)...More than 160 participants gathered this week for ... INITIATIVE conference. This year,s topic, "Synthe...rs, and medical researchers to explore the enginee...e emerging field of synthetic biology. , Bonnie ...ceton University and this year,s conference chair,...
(Date:11/23/2009)... only swine vaccine available for the H1N1 virus h...th the virus. The vaccination marks the first time...ith the pandemic flu., Iowa State University,s H... the vaccine this summer and has been shipping pre...nd Illinois for several weeks., The latest vacci...
Breaking Biology News(10 mins):The cause behind the characteristic shape of a long leaf revealed 2Synthetic biology offers new opportunities for interdisciplinary collaboration 2Iowa State researcher produces, ships only H1N1 vaccine available for swine 2Watson Pharmaceuticals Receives FDA Approval For Generic PLAN B 28R 29 49981 1Watson Pharmaceuticals Receives FDA Approval For Generic PLAN B 28R 29 49981 2Galichia Heart Hospital Partners with Mobile Surgery International to Develop Wichita based Center of Excellence with Global Convenience 28TM 29 12775 1Galichia Heart Hospital Partners with Mobile Surgery International to Develop Wichita based Center of Excellence with Global Convenience 28TM 29 12775 2Galichia Heart Hospital Partners with Mobile Surgery International to Develop Wichita based Center of Excellence with Global Convenience 28TM 29 12775 3Migraine Frequency Tied to Stroke Heart Attack Risk 49976 1Migraine Frequency Tied to Stroke Heart Attack Risk 49976 2Migraine Frequency Tied to Stroke Heart Attack Risk 49976 3
...trains of influenza showed genetic differences fro...virus flu shot was found to be effective in preven...ted-virus nasal spray vaccine also prevented illne...determined by laboratory confirmation of flu infec...rlier studies had suggested that the nasal spray, ...
...n to eat their fruit and vegetables. But once kids...ften go the way of Barbie dolls and power rangers.... fruits past adolescence. , Fisetin, a naturally o...and other fruits and vegetables, stimulates signal... researchers at the Salk Institute for Biological ...
...fornia, San Diego (UCSD) School of Medicine ? www.... the world to self-report adverse effects of stati... "This line of research is important because many ...cholesterol are familiar with the benefits of stat...r with the adverse experiences with these drugs th...
Other Biology News:Flu shot effective against drifted influenza, nasal spray vaccine less so 2Flu shot effective against drifted influenza, nasal spray vaccine less so 3A natural chemical found in strawberries boosts memory in healthy mice 2A natural chemical found in strawberries boosts memory in healthy mice 3Patients can report statins' adverse effects on new web site 2
Safety Glasses Dispensers from Terra Universal, Inc.
Dispensing Bins from Terra Universal, Inc.
...cept that it uses a deep-UV deuterium bulb, which ...ith a shutter (controlled via a TTL signal or swit... powerful, stable output from 215-400 nm. In addit...lable, providing a wavelength range of 190-400 nm....
...sis and mitochondrial membrane potential. The mito...n early indication of the initiation of cellular a...ollapse in the electrochemical gradient across the... in the membrane potential (YD). Loss of mitochond...
Biology Products: